Murine Model Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

  Vancouver, BC –  December 21, 2020 —  BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTC:LMNGF) (“BioVaxys”) announced today that further analysis of the data from a preclinical animal study (also known as the “murine model study”) of its haptenized viral protein vaccine technology show that BVX-0320, its Covid-19 vaccine candidate based on the Company’s haptenized viral protein platform, elicits a robust T-cell response against SARS-CoV-2.   Using a technique called flow cytometry, the BioVaxys team found that its haptenized SARS-CoV-2 s-spike vaccine activated CD4+ help...

Share this article VANCOUVER, British Columbia, Dec. 21, 2020 /CNW/ -- BioVaxys Technology Corp. ( CSE: BIOV, FRA:5LB, OTC:LMNGF) ("BioVaxys") announced today that further analysis of the data from a preclinical animal study (also known as the "murine model study") of its haptenized viral protein vaccine technology show that BVX-0320, its COVID-19 vaccine candidate based on the Company's haptenized viral protein platform, elicits a robust T-cell response against SARS-CoV-2. Using a technique called flow cytometry, the BioVaxys team found that its haptenized SARS-CoV-2 s-spike vaccine activate...

Share this article Share this article PALM BEACH,  Fla., Dec. 21, 2020 /PRNewswire/ -- Since the global outbreak that triggered the pandemic, scientists around the world have been working on potential treatments and vaccines for the new coronavirus disease known as COVID-19… and they have been making progress at a rapid pace, perhaps the fastest in history.  Several companies are working on antiviral drugs, some of which are already in use against other illnesses, to treat people who have COVID-19, which could provide the fastest track of all.  Other companies are working on vaccines tha...